Last reviewed · How we verify
Lovastatin Tablet
Lovastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.
Lovastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Used for Hypercholesterolemia, Primary prevention of coronary heart disease, Secondary prevention of coronary heart disease.
At a glance
| Generic name | Lovastatin Tablet |
|---|---|
| Also known as | Group A |
| Sponsor | National Taiwan University Hospital |
| Drug class | Statin (HMG-CoA reductase inhibitor) |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Lovastatin is a competitive inhibitor of HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis. By blocking this enzyme, lovastatin decreases intracellular cholesterol production, leading to upregulation of LDL receptors on hepatocytes and increased clearance of LDL cholesterol from the bloodstream. This results in significant reductions in serum LDL and total cholesterol levels.
Approved indications
- Hypercholesterolemia
- Primary prevention of coronary heart disease
- Secondary prevention of coronary heart disease
Common side effects
- Myalgia (muscle pain)
- Elevated liver enzymes (ALT/AST)
- Headache
- Rhabdomyolysis (rare)
- Gastrointestinal disturbance
Key clinical trials
- KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism (NA)
- Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis (EARLY_PHASE1)
- Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis (PHASE3)
- Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis (PHASE3)
- Antimicrobial and Anti-inflammatory Effects of Simvastatin as an Intracanal Medication (NA)
- Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC (PHASE1)
- A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants (PHASE1)
- Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lovastatin Tablet CI brief — competitive landscape report
- Lovastatin Tablet updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI